

Addendum:

Erratum

After issuing the Assessment Report (AR), the following amendments were made following comments raised by the manufacturer:

- p 23 in the AR: The date for the release of the new BCSH guidelines for follicular lymphoma was amended:

“Guidance specific to FL is due for publication in ~~August 2011~~ June 2011”

- p 28 in the AR: The wording relapsed/refractory was removed from the sentence detailing the indication for rituximab maintenance:

“Rituximab maintenance therapy is indicated for patients with ~~relapsed/refractory~~ FL responding to induction therapy with chemotherapy with or without rituximab.”

After issuing the Assessment Report (AR), the following amendments were made following comments raised by Healthcare Improvement Scotland :

- p 14: The error in transposing the description of systematic symptoms has been corrected as follows:
“Each stage of disease is divided into two subsets of patients according to the ~~absence~~ presence (A) or ~~presence~~ absence (B) of systematic symptoms.”

After issuing the Assessment Report (AR), the following amendments were made following the Appraisal Committee on the 11th August 2011:

- p.4: FCM was corrected to Fludarabine, cyclophosphamide and mitoxantrone (originally Fludarabine, chlorambucil and mitoxantrone)
- p.25, Table 5: R-FC was corrected to Fludarabine, cyclophosphamide and mitoxantrone (originally Fludarabine, chlorambucil and mitoxantrone)
- p.58: Table 13 Overall survival in the four included studies: The hazard ratio for the FL2000 trial was corrected to 0.69 (originally 1.46)

- p.115: Table 34: Treatment pathway incorporating maintenance: The two cells indicating second-line treatment for the <65 years were corrected in the R-CHOP/R-MCP column to R-HDT (+/- ASCT).
- P.138: Figure 27: The formatting has been altered to distinguish the different treatment arms:

